These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 37580808)

  • 1. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
    Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
    Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
    Yi J; Peng F; Zhao J; Gong X
    Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
    Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
    Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.
    Huang J; Sun W; Wang Z; Lv C; Zhang T; Zhang D; Dong W; Shao L; He L; Ji X; Zhang P; Zhang H
    J Exp Clin Cancer Res; 2022 Jan; 41(1):42. PubMed ID: 35090515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. m
    Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
    Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WTAP activates MAPK signaling through m6A methylation in VEGFA mRNA-mediated by YTHDC1 to promote colorectal cancer development.
    Ye M; Chen J; Yu P; Hu C; Wang B; Bao J; Lu F; Zhong Y; Yan L; Kan J; Bai J; Tian Y; Tang Q
    FASEB J; 2023 Aug; 37(8):e23090. PubMed ID: 37428639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
    Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
    Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.
    Zhang Z; Wang L; Zhao L; Wang Q; Yang C; Zhang M; Wang B; Jiang K; Ye Y; Wang S; Shen Z
    Clin Transl Med; 2022 Aug; 12(8):e940. PubMed ID: 35979628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms.
    He P; Liu X; Yu G; Wang Y; Wang S; Liu J; An Y
    Mol Cell Biochem; 2024 Jul; 479(7):1707-1720. PubMed ID: 38822192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GAS5 regulated by FTO-mediated m6A modification suppresses cell proliferation via the IGF2BP2/QKI axis in breast cancer.
    Yan Y; Ma J; Chen Q; Zhang T; Fan R; Du J
    Discov Oncol; 2024 May; 15(1):182. PubMed ID: 38782769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTO up-regulation induced by MYC suppresses tumour progression in Epstein-Barr virus-associated gastric cancer.
    Xu YY; Li T; Shen A; Bao XQ; Lin JF; Guo LZ; Meng Q; Ruan DY; Zhang QH; Zuo ZX; Zeng ZL
    Clin Transl Med; 2023 Dec; 13(12):e1505. PubMed ID: 38082402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALKBH5 decreases SLC7A11 expression by erasing m6A modification and promotes the ferroptosis of colorectal cancer cells.
    Luo J; Yu H; Yuan Z; Ye T; Hu B
    Clin Transl Oncol; 2023 Jul; 25(7):2265-2276. PubMed ID: 36820954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
    Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
    Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
    Yang Z; Cai Z; Yang C; Luo Z; Bao X
    EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALKBH5 promotes the proliferation of renal cell carcinoma by regulating AURKB expression in an m
    Zhang X; Wang F; Wang Z; Yang X; Yu H; Si S; Lu J; Zhou Z; Lu Q; Wang Z; Yang H
    Ann Transl Med; 2020 May; 8(10):646. PubMed ID: 32566583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of UCA1 by N6-methyladenosine RNA methylation modification promotes colorectal cancer progression.
    He RZ; Jiang J; Hu X; Lei M; Li J; Luo W; Duan L; Hu Z; Mo YY; Luo DX; Peng WX
    Cancer Cell Int; 2021 Nov; 21(1):616. PubMed ID: 34809621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of RNA N6-methyladenosine in primary Sjögren's syndrome.
    Xiao Q; Wu X; Deng C; Zhao L; Peng L; Zhou J; Zhang W; Zhao Y; Fei Y
    Front Med (Lausanne); 2022; 9():959388. PubMed ID: 36465909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.
    Wang F; Hu Y; Wang H; Hu P; Xiong H; Zeng Z; Han S; Wang D; Wang J; Zhao Y; Huang Y; Zhuo W; Lv G; Zhao G
    J Exp Clin Cancer Res; 2023 Oct; 42(1):267. PubMed ID: 37840133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased
    Luo Q; Gao Y; Zhang L; Rao J; Guo Y; Huang Z; Li J
    Biomed Res Int; 2020; 2020():5735279. PubMed ID: 32884942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.